Cerevel Therapeutics Moving to Cambridge Crossing

DivcoWest announced today that it has signed a 59,865 square-foot lease with Cerevel Therapeutics at Cambridge Crossing (CX), located at the intersection of Cambridge, Somerville, and Boston. Dedicated to bringing cutting-edge solutions to individuals impacted by nervous system diseases, Cerevel will join Philips North America at 222 Jacobs Street in 2020, making it the third fully leased commercial building at CX.

Cerevel Therapeutics is focused on the development of leading-edge treatments for neurological and neuropsychiatric diseases and is advancing a diversified portfolio of investigational therapies designed to address a broad range of central nervous system diseases, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction.

“With its proximity to leading life science companies, academic medical centers, and financial institutions, Cambridge Crossing will be a terrific location for Cerevel Therapeutics during this critical phase of growth and expansion,” said Tony Coles, executive chairperson of Cerevel Therapeutics. “The state-of-the-art office and laboratory space coupled with convenient access to public transportation and unique amenities will be key factors that help us continue to attract and retain top talent.”

With the addition of Cerevel Therapeutics, approximately 1.3 million square-feet of commercial space is now fully leased at CX, and a fourth building is now under construction, a 504,000 square-foot science and technology building at 250 Water Street. (Source: Cambridge Crossing Website, 07 August, 2019)